GlobeNewswire: Daxor Corporation Contains the last 10 of 185 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:32:04ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/25/2851555/0/en/Daxor-Corporation-Acquires-Volumex-and-Megatope-From-Its-Existing-Supplier-Along-With-Glofil-to-Enhance-Existing-Suite-of-Diagnostics.html?f=22&fvtc=4&fvtv=40542Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics2024-03-25T12:00:00Z<![CDATA[Expected to Improve Margins and Increase Revenue Streams]]>https://www.globenewswire.com/news-release/2024/03/22/2850911/0/en/Daxor-Corporation-to-Hold-Investor-Call-Discussing-Fiscal-Year-2023-Financial-Results-and-Corporate-Update-on-March-25-2024.html?f=22&fvtc=4&fvtv=40542Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 20242024-03-22T12:00:00Z<![CDATA[Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/03/18/2848105/0/en/Daxor-Corporation-CEO-and-President-Michael-Feldschuh-Provides-Corporate-Update-in-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=40542Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders2024-03-18T18:18:00Z<![CDATA[Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.]]>https://www.globenewswire.com/news-release/2024/03/18/2848106/0/en/Daxor-Corporation-Reports-Increase-in-NAV-to-7-08-Per-Share-and-31-8-Percent-Increase-in-Unaudited-Revenue-of-Operating-Division-for-the-Year-Ended-December-31-2023.html?f=22&fvtc=4&fvtv=40542Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 20232024-03-18T18:18:00Z<![CDATA[Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY]]>https://www.globenewswire.com/news-release/2024/03/11/2843720/0/en/Daxor-Announces-Sales-to-Three-New-Hospitals-Furthering-Expansion-of-Its-User-Base.html?f=22&fvtc=4&fvtv=40542Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base2024-03-11T12:00:00Z<![CDATA[Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance.]]>https://www.globenewswire.com/news-release/2024/03/08/2843076/0/en/Multi-Center-Study-Presented-by-Duke-at-Heart-Failure-Therapeutics-Conference-Highlights-Daxor-s-Unique-Clinical-Utility-for-Heart-Failure-Patients.html?f=22&fvtc=4&fvtv=40542Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients2024-03-08T13:00:00Z<![CDATA[Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates]]>https://www.globenewswire.com/news-release/2024/02/26/2835062/0/en/Daxor-Corporation-to-Exhibit-at-the-Technology-and-Heart-Failure-Therapeutics-Conference.html?f=22&fvtc=4&fvtv=40542Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference2024-02-26T13:00:00Z<![CDATA[Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.]]>https://www.globenewswire.com/news-release/2024/02/12/2827459/0/en/Daxor-Corporation-Starts-2024-with-Ongoing-Growth-in-New-Blood-Volume-Analyzer-Acquisitions.html?f=22&fvtc=4&fvtv=40542Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions2024-02-12T13:00:00Z<![CDATA[Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor’s BVA-100™ (Blood Volume Analyzer) in January, marking a strong start to 2024.]]>https://www.globenewswire.com/news-release/2024/02/07/2825148/0/en/Daxor-Corporation-Closes-Q4-2023-with-Growth-in-New-Sales-to-Hospital-Systems-and-Increased-Utilization-of-its-BVA-100-Blood-Volume-Diagnostic-Across-the-U-S-at-Existing-Accounts.html?f=22&fvtc=4&fvtv=40542Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts2024-02-07T13:00:00Z<![CDATA[Daxor's ezBVA Lab Service Plays a Significant Role in Driving Growth and Fostering Widespread Adoption]]>https://www.globenewswire.com/news-release/2024/01/29/2818865/0/en/Daxor-Corporation-to-Exhibit-at-the-Society-of-Nuclear-Medicine-and-Molecular-Imaging-Mid-Winter-and-American-College-Nuclear-Medicine-Annual-Meeting.html?f=22&fvtc=4&fvtv=40542Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting2024-01-29T13:00:00Z<![CDATA[Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.]]>